Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors

NEXT STORY
Oncology Venture provides news on its clinical development projects dovitinib, 2X‑121 and LiPlaCis
PREV STORY
Helix BioPharma Corp. Closes Second Tranche of Private Placement
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Canada Insulin Pump & CGM Market Report 2018: A Potential CAD 1 Billion Market by 2024

Dublin, June 06, 2018 (GLOBE NEWSWIRE) -- The "Canada Insulin Pump & CGM Market, ...

author_avatar
NASDAQ Market News

Azul Cosmetic Surgery Set to Sponsor a Medical Student for Four Years of College Through the University of Michigan Medical School

FT. MYERS, Fla., Dec. 03, 2015 (GLOBE NEWSWIRE) -- With the cost of a ...

author_avatar
NASDAQ Market News

IRADIMED Names John McCreery Chief Operating Officer

WINTER SPRINGS, Fla., March 30, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that ...

author_avatar
NASDAQ Market News